Shanghai-based ALLYRNA has raised more than RMB 100 million in Seed+ financing to advance a new generation of small-molecule cancer therapies derived from RNA epigenetics, including potential radiotherapy and immunotherapy sensitizers for difficult-to-treat tumors.
SHANGHAI, August 31, 2026 — Chinese biotechnology startup ALLYRNA (上海艾联纳医药科技有限公司) has completed a Seed+ financing exceeding RMB 100 million, providing new capital to advance its emerging pipeline of first-in-class small-molecule oncology drugs built around discoveries in RNA epigenetics.
The financing was co-led by Shanghai State-owned Capital Investment Leading Fund (上海国投先导), TTM Capital (齐济投资), and Shanghai Future-oriented Industries Fund (上海未来产业基金). CASSTAR (中科创星) participated as a new investor, while existing shareholders Gaorong/Jifeng and Plaisance Capital continued to increase their investments. (finance.eastmoney.com)
Proceeds will be used to advance ALLYRNA’s core R&D programs, optimize drug candidates, strengthen its preclinical development capabilities and expand its global intellectual-property portfolio. The company also plans to recruit additional scientific talent and accelerate translation of its academic discoveries into drug candidates. (api3.cls.cn)
The financing comes roughly a year after ALLYRNA disclosed a nearly US$10 million seed round, underscoring growing investor interest in the company’s attempt to translate fundamental discoveries in RNA biology into novel cancer medicines. TTM Capital’s previous ALLYRNA financing announcement
Founded by RNA Epigenetics Pioneer Chuan He
ALLYRNA was established in Shanghai in 2024 by Professor Chuan He (何川), one of the world’s leading scientists in RNA epigenetics and chemical biology.
He is the John T. Wilson Distinguished Service Professor at the University of Chicago and an investigator at the Howard Hughes Medical Institute. He received his Ph.D. from MIT and subsequently conducted postdoctoral research at Harvard University.
His laboratory is particularly known for pioneering work in RNA modifications and epitranscriptomics — the study of chemical modifications that dynamically regulate RNA molecules and influence gene expression.
Professor He received the 2023 Wolf Prize in Chemistry for his contributions to understanding reversible RNA methylation and its role in regulating gene expression. He was subsequently elected to the American Academy of Arts and Sciences in 2024.
ALLYRNA was created to translate discoveries emerging from this field into therapeutic medicines.
Rather than developing RNA molecules themselves as drugs, the company’s strategy centers on small molecules capable of modulating biological pathways revealed through RNA epigenetics research.
That distinction gives ALLYRNA a potentially unusual position within China’s rapidly expanding RNA therapeutics ecosystem.
Turning RNA Epigenetics Into Cancer Medicines
RNA was once regarded largely as an intermediary carrying genetic instructions from DNA to proteins.
Research over the past decade has revealed a much more dynamic system.
RNA molecules can carry chemical modifications that alter their stability, translation, localization and interactions with other molecules. These modifications can profoundly influence cellular behavior and are increasingly implicated in cancer, immune regulation and other diseases.
ALLYRNA is attempting to exploit those mechanisms therapeutically.
The company describes itself as a biotechnology company focused on first-in-class small-molecule drug discovery, with its scientific foundation built on original discoveries in RNA epigenetics.
Its principal areas of research include:
Tumor therapy → radiotherapy sensitization → immunotherapy sensitization
Instead of competing directly with established checkpoint inhibitors or cytotoxic therapies, ALLYRNA is exploring whether manipulating RNA-regulatory mechanisms can make tumors more vulnerable to existing cancer treatments.
A Proprietary Radiotherapy and Immunotherapy Sensitizer Platform
One of ALLYRNA’s central assets is its proprietary technology platform for developing radiotherapy and immunotherapy sensitizers.
Radiotherapy remains a cornerstone of cancer treatment, but tumors can develop intrinsic or acquired resistance to radiation-induced damage.
Similarly, immune checkpoint inhibitors have transformed oncology, but only a subset of patients responds durably to treatment.
ALLYRNA’s strategy is to identify RNA-regulatory mechanisms that contribute to those resistance pathways and develop small molecules capable of disrupting them.
Conceptually, the approach could work through:
RNA epigenetic target → small-molecule modulation → altered tumor biology → increased sensitivity to radiation or immunotherapy → enhanced antitumor response
The company has not yet publicly disclosed the molecular targets underlying its lead programs, making it difficult to independently evaluate their precise mechanisms or competitive positioning.
ALLYRNA nevertheless says its core programs have generated positive preclinical progress. (sohu.com)
Pipeline Targets High-Unmet-Need Cancers
ALLYRNA’s pipeline currently focuses on several cancers where treatment resistance and limited therapeutic options remain significant challenges.
| Disease Area | ALLYRNA’s Development Focus | Current Disclosed Stage |
|---|---|---|
| Small cell lung cancer (SCLC) | Novel small-molecule / sensitizer approach | Preclinical |
| Rectal cancer | Radiotherapy-related therapeutic strategy | Preclinical |
| Leukemia | RNA epigenetics-derived oncology approach | Preclinical |
| Pancreatic cancer | Novel sensitization / oncology strategy | Preclinical |
| Additional tumors | Radiotherapy and immunotherapy sensitization | Discovery / preclinical |
ALLYRNA has not publicly disclosed detailed candidate names, molecular targets or individual development timelines for these programs.
Its lead program remains preclinical, although recent reporting indicates the company intends to use the new financing to advance its first differentiated small-molecule oncology candidate through preclinical development and toward an Investigational New Drug (IND) application.
That IND filing could become the company’s most important near-term milestone.
Small Cell Lung Cancer Represents an Important Opportunity
Among ALLYRNA’s disclosed disease areas, small cell lung cancer represents a particularly high-unmet-need opportunity.
SCLC is an aggressive neuroendocrine malignancy characterized by rapid proliferation, early metastasis and frequent relapse after initial treatment.
Although the disease can initially respond to chemotherapy and radiotherapy, resistance frequently develops.
That makes SCLC a potentially attractive setting for a therapeutic designed specifically to sensitize cancer cells to established treatments.
ALLYRNA has not disclosed whether SCLC is the indication for its lead candidate, however, so the relationship between individual pipeline assets and the company’s disclosed tumor indications remains unclear.
Potential Role in Rectal Cancer Radiotherapy
Rectal cancer represents another particularly logical application for ALLYRNA’s radiotherapy-sensitization technology.
Radiotherapy is frequently incorporated into treatment strategies for locally advanced rectal cancer, often alongside chemotherapy and surgery.
However, the degree of tumor response varies considerably among patients.
A small-molecule drug capable of selectively increasing tumor sensitivity to radiation could potentially enhance response while avoiding the systemic toxicity associated with simply increasing radiation exposure.
This remains a theoretical application until ALLYRNA discloses the specific mechanism and preclinical evidence supporting its programs.
Immunotherapy Sensitization Could Broaden the Opportunity
ALLYRNA’s immunotherapy-sensitizer strategy potentially expands the platform beyond cancers routinely treated with radiation.
Immune checkpoint inhibitors targeting pathways such as PD-1/PD-L1 have become standard therapies across numerous tumor types, but primary and acquired resistance remain major problems.
RNA epigenetic pathways can influence immune-cell behavior, tumor antigen presentation, inflammatory signaling and the tumor microenvironment.
Modulating those pathways with small molecules could potentially convert tumors that respond poorly to immunotherapy into more immunologically responsive cancers.
ALLYRNA’s ability to identify drug-accessible nodes within those RNA-regulatory pathways will therefore be an important determinant of whether its platform can generate differentiated medicines.
Seed+ Round Follows Nearly $10 Million Seed Financing
ALLYRNA’s new financing follows a seed round completed in 2025.
In August 2025, the company announced that it had raised nearly US$10 million, with the round co-led by TTM Capital, Gaorong Ventures and Jifeng Ventures, alongside strategic participation from U.S.-based Plaisance Capital. TTM Capital — ALLYRNA seed financing announcement
At the time, ALLYRNA said the capital would support its oncology pipeline and radiotherapy-sensitizer research.
TTM Capital has been involved with the company since its establishment, providing support ranging from company registration to team formation and platform development.
The new Seed+ financing substantially expands that investor group.
| Financing | Timing | Amount | Key Investors |
|---|---|---|---|
| Seed | 2025 | Nearly US$10M | TTM Capital, Gaorong, Jifeng, Plaisance Capital |
| Seed+ | August 2026 | >RMB 100M | Shanghai State-owned Capital Investment Leading Fund, TTM Capital, Shanghai Future-oriented Industries Fund, CASSTAR, Gaorong/Jifeng, Plaisance Capital |
The continued participation of existing shareholders alongside several new institutional investors provides ALLYRNA with additional resources as it transitions from early discovery toward formal preclinical development. (finance.eastmoney.com)
Financing to Support IND-Enabling Development
Unlike some early biotech financing rounds focused primarily on platform construction, ALLYRNA’s latest funding appears increasingly directed toward candidate development and clinical translation.
The company plans to use the proceeds to:
- advance core R&D programs and optimize candidate molecules;
- establish and strengthen its preclinical development capabilities;
- progress its first differentiated oncology small-molecule candidate toward an IND filing;
- expand its global intellectual-property portfolio; and
- strengthen its scientific and drug-development team. (sohu.com)
This marks an important transition for a company founded only two years ago.
From Academic Discovery to Drug Development
ALLYRNA represents part of a broader trend in China’s biotechnology sector: the creation of venture-backed drug companies around fundamental discoveries made by internationally recognized Chinese scientists.
In ALLYRNA’s case, the scientific foundation is particularly distinctive.
Much of the industry’s RNA-related investment has concentrated on therapeutic modalities such as siRNA, antisense oligonucleotides, mRNA and RNA editing.
ALLYRNA is approaching RNA biology from another direction.
The company is using discoveries in RNA epigenetics to identify drug targets and biological mechanisms, but intends to intervene primarily with conventional small molecules.
That could potentially combine the novelty of emerging RNA biology with some of the familiar development and manufacturing characteristics of small-molecule drugs.
The central question is whether those insights can generate clinically meaningful therapeutic effects.
What to Watch Next
ALLYRNA remains an early-stage biotechnology company, and much about its pipeline is still undisclosed.
Most importantly, the company has yet to reveal the chemical structure, target, development code or detailed mechanism of action of its lead candidate.
Those disclosures will provide the first opportunity to assess how differentiated its science is from other emerging approaches to cancer sensitization.
The next major milestones are therefore likely to include selection or disclosure of the lead development candidate, publication of detailed preclinical data, completion of IND-enabling studies and submission of its first IND application.
If ALLYRNA can successfully translate Professor Chuan He’s pioneering work in RNA epigenetics into druggable cancer mechanisms, the company could establish a new therapeutic category at the intersection of epitranscriptomics, small-molecule drug discovery, radiotherapy and cancer immunotherapy.
Its new RMB 100 million-plus Seed+ financing provides the capital to begin testing that proposition.
References
- STAR Market Daily / CLS — ALLYRNA Completes RMB 100M+ Seed+ Financing
- Eastmoney — ALLYRNA Raises More Than RMB 100 Million in Seed+ Round
- TTM Capital — ALLYRNA Seed Financing and Company Technology Overview
- TTM Capital — English Announcement of ALLYRNA’s Previous Financing
- Jixin — ALLYRNA Seed+ Financing and Investor Details
- VBData — ALLYRNA Company and Financing Profile
- Pharnexcloud — ALLYRNA Financing and RNA Epigenetics Platform Overview
